The definitive benchmark for infectious vaccine dealmaking
Infectious vaccine partnering is shaped by global health priorities, outbreak-driven demand, and collaboration between public and private sector stakeholders, with deal structures reflecting both strategic preparedness and commercial considerations.This report provides a comprehensive and structured analysis of 590+ infectious vaccine collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.
Establish a clear view of market standards
The report enables a precise understanding of how infectious vaccine deals are structured in practice, allowing you to:
- Benchmark comparable transactions with confidence
- Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
- Define realistic market parameters
- Clear insight into how deal terms vary by technology platform, indication, and partner profile
- Support valuation and structuring decisions with evidence
- Ground internal discussions in real transaction data rather than assumptions
- Understand how leading companies approach dealmaking
- Visibility into partner behaviour and recurring deal structures across a policy-influenced and globally coordinated landscape
- Full visibility into deal structure and execution
This includes:
- Rights granted and retained
- Development and commercialization responsibilities
- Financial structures and payment triggers
- Key contractual provisions and protections
Designed for real-world BD and strategy use
The report is widely used to:
- Structure and benchmark live transactions
- Prepare for negotiations with well-defined market context
- Evaluate partnership opportunities and counterparties
- Support internal strategy with robust, defensible data
What’s included?
- 590+ infectious vaccine collaboration and licensing deals
- Financial terms, including upfronts, milestones, and royalties where disclosed
- Fully searchable deal directory (by company, technology, and indication)
- Direct access to SEC-filed agreements and source documents
- Analysis of deal trends, key transactions, and active dealmakers
- A trusted, evidence-based reference for infectious vaccine dealmaking
Table of Contents
Executive SummaryChapter 1 - IntroductionChapter 6 - Infectious vaccine dealmaking by technology type
Chapter 2 - Trends in infectious vaccine dealmaking
Chapter 3 - Leading infectious vaccine deals
Chapter 4 - Most active infectious vaccine dealmakers
Chapter 5 - Infectious vaccine contracts dealmaking directory
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2A
- A*STAR’ Institute of Molecular and Cell Biology
- ABEC
- Abera Bioscience
- Abnova
- AbVacc
- Academy of Military Medical Sciences (China)
- AchilleS Vaccines
- Adaptive Phage Therapeutics
- AdaptVac
- Adjuvance Technologies
- Aduro BioTech
- Advaccine Biotechnology
- Advanced BioNutrition
- Advanced BioScience Laboratories
- Aegis Life
- Aelix Therapeutics
- Aerogen
- Affinivax
- Afrigen Biologics
- AGC Biologics
- AIM ImmunoTech
- Akers Biosciences
- Akshaya Bio
- Akston Biosciences
- Albany Molecular Research
- Alcami
- Aldevron
- Algenex
- Alopexx
- Altimmune
- American Gene Technologies
- American Type Culture Collection (ATCC)
- AmerisourceBergen
- Amyris
- AnGes MG
- Aphios
- Appili Therapeutics
- Applied DNA Sciences
- Aragen Bioscience
- Arcturus Therapeutics
- Ardigen
- Aridis Pharmaceuticals
- Artes Biotechnology
- Astellas Pharma
- AstraZeneca
- AuraVax Therapeutics
- Aurobindo Pharma
- Avid Bioservices
- Barinthus Biotherapeutics
- Batavia Biosciences
- Battelle
- Bavarian Nordic
- Baylor College
- Baylor College of Medicine
- Beijing Minhai Biotechnology
- Beth Israel Deaconess Medical Center
- Bharat Biotech
- BIA Separations
- Bill and Melinda Gates Foundation
- Bilthoven Biologicals
- Binex
- Bintai Kinden
- BioComo
- Biofabri
- Biofactura
- BioIVT
- Biolexis
- BioLife Solutions
- Biological E
- Biomedical Advanced Research and Development Authority
- BiondVax
- BioNet Holding
- BioNTech
- BioSun Pharmed
- Biotechnology Industry Research Assistance Council
- BioVaxys
- Blackstone
- Blanver
- Blue Water Vaccines
- BlueWillow Biologics
- Boehringer Ingelheim
- Botanical Solution
- Bpifrance
- BravoVax
- Brickell Biotech
- Brii Biosciences
- BTG
- Burnet Institute
- Butantan Institute
- California Institute for Regenerative Medicine
- CanSinoBIO
- Capricor Therapeutics
- CARB-X
- CaroGen
- Catalent
- Catholic University Leuven
- CCT Research
- Celdara Medical
- Celonic
- Centers for Disease Control and Prevention
- Changchun BCHT Biotechnology
- Charles River Laboratories
- Chengdu Kanghua Biological Products
- Children's Hospital Boston
- Chimeron Bio
- China National Biotech Group (CNBG)
- CimCure
- Cincinnati Children’s Hospital Medical Center
- CIRION BioPharma Research
- Citranvi Biosciences
- City College of New York
- City of Hope
- Clarametyx Biosciences
- ClearB Therapeutics
- ClearPath
- Clover Biopharmaceuticals
- Coalition for Epidemic Preparedness Innovations
- Cobra Biologics
- Codagenix
- Codiak BioSciences
- Colombia Ministry of Health and Social Protection
- Colorado State University
- ConserV Bioscience
- COVAXX
- Cristal Therapeutics
- Croda
- Crozet BioPharma
- CSIRO
- CSL
- Curapath
- Curative Biotechnology
- CureVac
- CVC
- CyanVac
- Cystron Biotech
- Cytiva
- Cytovance Biologics
- Dalton Pharma Services
- Debiopharm
- Defense Advanced Research Projects Agency
- Defense Threat Reduction Agency
- Department of Defence
- Department of Defense
- Department of Health and Human Services
- DIOSynVax
- Dr. Reddy's Laboratories
- Duke-NUS Graduate Medical School Singapore
- Dyadic International
- Dynavax Technologies
- DynPort Vaccine Company
- Elaris
- Elixirgen
- Emergent BioSolutions
- Emergex Vaccines
- Emmes
- Emmes Group
- Emory University
- EmVenio Research
- Endo International
- Enesi Pharma
- Engility
- Ennaid Therapeutics
- Entos Pharmaceuticals
- Epivax
- EpiVax Therapeutics
- Epygen Biotech
- eTheRNA immunotherapies
- Ethris
- Eurocine Vaccines
- Eurofarma
- European Union
- Evaxion Biotech
- Everest Medicines
- EVQLV
- ExcellGene
- Excivion
- eXmoor Pharma
- Exothera
- ExpreS2ion Biotechnologies
- Eyam Vaccines and Immunotherapeutics
- Eyegene
- Fareva Holding
- Farmacore Biotechnology
- Fatro
- Federal Ministry of Education and Research (BMBF)
- Fina Biosolutions
- Flow Pharma
- FluGen
- Food and Drug Administration (FDA)
- Fosun Pharmaceutical
- Foundation for Biomedical Research and Innovation
- Frazier Healthcare Ventures
- Frederick National Laboratory For Cancer Research
- Fred Hutchinson Cancer Research Center
- Gamaleya National Center
- GC Pharma
- GE Healthcare
- Generex Biotechnology
- Genetic Immunity
- Geneva Foundation
- Genevant Sciences
- Genexine
- Gennova Biopharmaceuticals
- Genocea Biosciences
- Genomma Lab Internacional
- George Mason University
- Georgia State University Research Foundation (GSURF)
- Georgia Tech Research Corporation
- GeoVax
- German Cancer Research Center
- German Center for Infection Research
- German Government
- Gilead Sciences
- Ginkgo BioWorks
- GlaxoSmithKline Biologicals
- Global Virus Network
- Government of Canada
- Government of India
- Government of South Korea
- Grand River Aseptic Manufacturing
- Greenlight Biosciences
- Greenwich LifeSciences
- Gritstone Bio
- GSK
- GTP Bioways
- Halix
- HaloVax
- HanaVax
- Harro Hofliger
- Harvard University
- Hawaii Biotech
- HDT Bio
- Heat Biologics
- Helocyte
- Henry M. Jackson Foundation
- HilleVax
- Horizon Europe
- Hoth Therapeutics
- Howard Hughes Medical Institute (HHMI)
- HSS
- hVIVO
- Iaso Therapeutics
- Icahn School of Medicine at Mount Sinai
- Icon
- Iconovo
- Icosavax
- IDT Biologika
- ILiAD Biotechnologies
- ImmBio
- Immune System Regulation
- ImmunityBio
- Immunomic Therapeutics
- ImmunoPrecise Antibodies
- ImmunoScape
- Immunovaccine
- Immuron
- Imophoron
- Imperial College London
- Indian Council of Medical Research
- Infectious Disease Research Institute (IDRI)
- Infor
- InnoCentive
- Innovate UK
- Innovo
- Inovio
- Inovio Pharmaceuticals
- Inserm Transfert
- InSilicoTrials
- Inspirevax
- Institute for Bioscience and Biotechnology Research
- Institut Pasteur
- INTACT Solutions
- Integral Molecular
- Integrated BioTherapeutics
- International AIDS Vaccine Initiative
- International Vaccine Institute (IVI)
- Intravacc
- IQVIA
- Israeli National Authority for Technological Innovation
- Israel Institute for Biological Research
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Research & Development
- Jenner Institute
- JSC Pharmadis
- Jubilant Hollisterstier
- Kansas State University
- Karolinska Institute
- KBI BioPharma
- KELTIC Pharma
- Kemin Industries
- Kenya Medical Research Institute
- Kermode Biotechnologies
- King Abdullah University for Science and Technology
- King Saud University
- Kleo Pharmaceuticals
- KM Biologics
- Korea Advanced Institute of Science and Technology
- La Jolla Institute for Allergy & Immunology
- Lawrence Livermore National Laboratory
- Leidos
- Leukocare
- LimmaTech Biologics
- LinKinVax
- LiteVax
- Longeveron
- Lonza
- Lumos Pharma
- Macquarie University
- Magnetrap
- Maryland Technology Development Corporation
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- McMaster University
- MedGene Bioscience
- Medicago
- Medical University of Vienna
- MediciNova
- MediGene
- Medigen Vaccine Biologics
- Medison Pharma
- Medlab Clinical
- Medytox
- Mellow Hope Bio Chem
- Merck and Co
- Merck KGaA
- Merck Sharpe & Dohme
- Metaclipse Therapeutics
- Mexican National Technology and Science Council
- Micron Biomedical
- Mid-Atlantic BioTherapeutics
- Midatech Pharma
- Mie University
- MigVax
- MilliporeSigma
- MinervaX
- Ministry of Health (Denmark)
- Moderna
- MphRx
- MSD
- MSD Wellcome Trust Hilleman Laboratories
- Mundo Sano
- Mymetics
- NanoBio
- NanoPass Technologies
- Nant Africa
- NantKwest
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Cholera and Enteric Diseases
- National Institute of Hygiene and Epidemiology
- National Institute of Infectious Diseases
- National Institute of Vaccines and Medical Biologicals
- National Institute on Deafness and Other Communication Disorders
- National Institutes of Health
- National Research Council Canada
- National Research Council of Canada
- National Science Foundation
- Nature Technology
- Navigo Proteins
- New Zealand's Foundation for Research
- Science and Technology
- Nexelis
- Noachis Terra
- Nobelpharma
- Northern RNA
- Novartis
- Novavax
- Novo
- NRx Pharmaceuticals
- Nuance Pharma
- NuGenerex Immuno-Oncology
- Nykode Therapeutics
- Ocugen
- Ohio State University
- Ology Bioservices
- Omniose
- Oragenics
- Oramed Pharmaceuticals
- Oravax Medical
- Orexo
- OSE Immunotherapeutics
- Osivax
- Oswaldo Cruz Foundation (Fiocruz)
- Owkin
- Oxgene
- Pacific GeneTech
- Panacea Biotech
- PATH (Appropriate Technology in Health)
- PaxVax
- PDS Biotechnology
- Peter Doherty Institute for Infection and Immunity
- Pfizer
- Pharm-Olam International
- PharmaJet
- Pharma Science
- Phil
- PlantForm
- PnuVax
- Pohang University Of Science And Technology
- PolyPeptide Group
- POSCO International
- Precision NanoSystems
- Precision Virologics
- Premas Biotech
- Prestige BioPharma
- Primrose Bio
- ProBioGen
- Probiomed
- Probius
- Profectus Biosciences
- Prokarium
- Protein Sciences
- Provention Bio
- Providence Therapeutics
- PT Bio Farma
- Public Health Agency of Canada
- Public Health England
- Public Health Vaccines
- Quebec Government
- Quratis
- R-Pharm
- Rabian
- Ragon Institute
- Rapid Dose Therapeutics
- Rapid Micro Biosystems
- Rational Vaccines
- Recipharm
- Redbiotec
- Refana
- Regeneron Pharmaceuticals
- ReiThera
- Rentschler Biotechnologie
- Repligen
- Reyon Pharmaceuticals
- Rockefeller University
- RocketVax
- Rokote Laboratories
- Rubic One Health
- Russian Direct Investment Fund
- Sabin Vaccine Institute
- Saiba
- Samsung Biologics
- Sanaria
- Sanofi
- Sanofi-Pasteur
- SaponiQx
- Sartorius
- Satio
- Scandinavian Biopharma
- Science 37
- SciSafe
- Scottish Enterprise
- Scripps Research Institute
- Selexis
- Sementis
- Senai Cimatec
- Seoul National University
- Seqirus
- Serum Institute of India
- Shanghai Hile Bio-technology
- Shionogi
- Shionogi Pharma
- Sinergium Biotech
- Sinotek-Advocates International Industry Development
- Sinovac Biotech
- SiO2 Medical Products
- SK Bioscience
- SmartPharm Therapeutics
- Smiths Medical
- Soligenix
- Sorrento Therapeutics
- Southern Research Institute
- Spicona
- SpyBiotech
- St. Jude Children's Research Hospital
- Stanford University
- Strategic Vaccines
- Sumaya Biotech
- Sunstone Capital
- SutroVax
- Symvivo
- Synairgen
- Syngene International
- Tabuk Pharmaceutical
- Takeda Pharmaceutical
- Takis Biotech
- Talem Therapeutics
- Technical University of Denmark (DTU)
- TechnoVax
- Texas A&M University
- Texas Biomedical Research Institute
- Texas Children’s Hospital
- TFF Pharmaceuticals
- The International AIDS Vaccine Initiative
- The Medical Research
- Infrastructure
- and Health Services Fund of the Tel Aviv Medical Center
- Themis Bioscience
- The Native Antigen Company
- Therapyx
- Thermo Fisher Scientific
- Thomas Jefferson University
- Tianjin CanSino Biotechnology
- Tiba Biotech
- TONIX Pharmaceuticals
- Trans-Hit Bio
- Translate Bio
- Transtoxbio
- Trianni
- TriLink BioTechnologies
- Tufts University
- UK Government
- UMN Pharma
- United Nations Children Fund
- Univercells
- University Health Network
- University of Adelaide
- University of Alabama at Birmingham
- University of Alberta
- University of British Columbia
- University of California
- Davis
- University of California Berkeley
- University of Chicago
- University of Edinburgh
- University of Georgia
- University of Hawaii
- University of Houston
- University of Liverpool
- University of Maryland
- University of Maryland School of Medicine
- University of Miami
- University of Miami Miller School of Medicine
- University of Montreal
- University of Nebraska
- University of New South Wales
- University of Oxford
- University of Queensland
- University of Saskatchewan
- University of Southampton
- University of Sydney
- University of Tennessee
- University of Texas
- University of the Witwatersrand
- University of Tokyo
- University of Washington
- University of Wisconsin-Madison
- University of Zaragoza
- US Air Force
- US Army
- US Army Medical Research and Material Command
- US Army Medical Research Institute of Infectious Diseases
- US Biologic
- US Department of Agriculture
- US Government
- Utrecht University
- Vaccitech
- Vaccizone
- Vactech
- Valneva
- Valo Therapeutics
- Variation Biotechnologies
- VaxAlta
- Vaxart
- Vaxcyte
- Vaxeal
- Vaxess Technologies
- Vaxil BioTherapeutics
- Vaxinano
- Vaxine
- VaxNewMo
- VaxThera
- Vaxxas
- VBI Vaccines
- Veristat
- Verndari
- Versatope Therapeutics
- Vetoquinol
- Vinbiocare Biotechnology
- Viravaxx
- Vir Biotechnology
- VitriVax
- ViveBio
- Voltron Therapeutics
- Wageningen University
- Walter Reed Army Institute of Research
- Washington University in St Louis
- Wellcome Trust
- Westport Bio
- Wipro
- WuXi Biologics
- Xenetic Biosciences
- Yale University
- Zhifei Lvzhu Biopharmaceutical
- Zoetis
- Zolovax
- Zuellig Pharma China
- Zydus Cadila
- ZYUS Life Sciences
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
